瑞普生物(300119.SZ):持股5%以上股東樑武增加一致行動人及持股在一致行動人之間內部轉讓計劃
格隆匯 10 月 22日丨瑞普生物(300119.SZ)公佈,公司於2020年10月21日收到持股5%以上股東樑武的告知函,因家庭資產規劃需要,樑武擬以大宗交易方式轉讓不超過800萬股(含本數)給其本人為唯一所有人的私募基金產品,同時與該私募基金產品簽署一致行動人協議。此次股份變動系持股5%以上股東及一致行動人之間內部進行的轉讓,不涉及向市場減持,不會導致該持股5%以上股東及一致行動人合計持股比例和數量發生變化。
此計劃實施前,樑武及一致行動人持有公司股份3296.0221萬股,佔公司總股本的8.15%;此計劃實施後,樑武及一致行動人合計持股數量和持股比例保持不變,仍為3296.0221萬股,佔總股本的8.15%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.